About Uncharacterized protein C21orf58
Uncharacterized protein C21orf58 (C21orf58) is a protein
from Homo sapiens identified by UniProt accession
P58505, 322 residues long.
MolForge cross-references it against 0 known binders and
72 disease associations.
Target properties
| Protein name | Uncharacterized protein C21orf58 |
|---|
| UniProt accession | P58505 |
|---|
| Gene | C21orf58 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 322 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (72)
Diseases linked to this target (Open Targets).
- microcephalic osteodysplastic primordial dwarfism · score 0.15
- leukocyte count · score 0.15
- heel bone mineral density · score 0.12
- serum albumin measurement · score 0.11
- monocyte percentage of leukocytes · score 0.09
- viral load · score 0.08
- hepatocellular carcinoma · score 0.07
- early-onset non-syndromic cataract · score 0.07
- type 2 diabetes mellitus · score 0.06
- Cataract-microcornea syndrome · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P58505-F1 | alphafold | PREDICTED | 59.87 | — |
Amino-acid sequence (322 residues)
MARSRLPATS LRKPWKLDRQ KLPSPDSGHS LLCGWSPGGK ARPAGNTGAW APAEQFFPAS NRTREGGGLW PPLPLQSSPA APTMLDSSAA EQVTRLTLKL LGQKLEQERQ NVEGGPEGLH LEPGNEDRPD DALQTALKRR RDLLQRLREQ HLLDELSRAQ AWSGPSRGAL GSALPPELPP TGILPTASPS PLAPDPPRII LPTVPQPPAT IIQQLPQQPL IAQIPPPQAF PTQRSGSIKE DMVELLLLQN AQVHQLVLQN WMLKALPPAL QDPPHVPPRV PRAARPRLPA VHHHHHHHHA VWPPGAATVL QPAPSLWTPG PP
Explore Uncharacterized protein C21orf58 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets